PATH's approach to product introduction in developing countries.
Health interventions developed for wealthy nations are difficult to introduce in developing countries due to a lack of sufficient technological, financial, political, or infrastructural resources. Increasingly, however, product developers are creating new technologies that meet the needs of low-resource settings. Experience has shown that many activities must be undertaken to prepare health systems to accept and embrace new, improved, or under-utilized health technologies. This article describes three health technologies--a diagnostic test for vitamin A deficiency, new cervical cancer vaccines, and the vaccine vial monitor--that PATH, a global health organization, has helped advance for developing-country markets.
Harner-Jay
Claudia
C
PATH, Technology Solutions, Program Officer, 1455 NW Leary Way, Seattle, Washington 98107, USA. charner@path.org
Sherris
Jacqueline
J
D002851:Chromatography, High Pressure Liquid; D003906:Developing Countries; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D053918:Papillomavirus Vaccines / Q000008:administration & dosage; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000517:prevention & control*; D014612:Vaccines; D014802:Vitamin A Deficiency / Q000175:diagnosis
D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines; D014612:Vaccines